retinitis pigmentosa therapy (Cue Biotech)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameretinitis pigmentosa therapy (Cue Biotech)
Drug Alias Namerhodopsin inhibitor (Cue Biotech)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionG-protein coupled receptor antagonists
TargetsG-protein coupled receptor
Therapy Area/IndicationsRetinitis Pigmentosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCaden Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCaden Biosciences Inc
Active IndicationsN/A
Inactive IndicationsRetinitis Pigmentosa

Other Information

ATC CodeN/A
Related LinksN/A